

# Alex Mackenzie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5204211/publications.pdf>

Version: 2024-02-01

42  
papers

3,491  
citations

516710

16  
h-index

315739

38  
g-index

42  
all docs

42  
docs citations

42  
times ranked

3599  
citing authors

#	ARTICLE	IF	CITATIONS
1	Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. <i>Nature</i> , 1996, 379, 349-353.	27.8	982
2	The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. <i>Cell</i> , 1995, 80, 167-178.	28.9	969
3	Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. <i>Nature Genetics</i> , 1996, 12, 241-247.	21.4	732
4	DNM1L-related mitochondrial fission defect presenting as refractory epilepsy. <i>European Journal of Human Genetics</i> , 2016, 24, 1084-1088.	2.8	113
5	Pyridoxine-Dependent Epilepsy in Zebrafish Caused by Aldh7a1 Deficiency. <i>Genetics</i> , 2017, 207, 1501-1518.	2.9	81
6	NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease. <i>European Journal of Neuroscience</i> , 2001, 14, 391-400.	2.6	72
7	Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. <i>Human Molecular Genetics</i> , 2013, 22, 3415-3424.	2.9	52
8	Neuronal apoptosis inhibitory protein, NAIP, is an inhibitor of procaspase-9. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 958-964.	2.8	48
9	Mouse lysine catabolism to amino adipate occurs primarily through the saccharopine pathway; implications for pyridoxine dependent epilepsy (PDE). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 121-128.	3.8	43
10	Molecular Analysis of Cystinosis: Probable Irish Origin of the Most Common French Canadian Mutation. <i>European Journal of Human Genetics</i> , 1999, 7, 671-678.	2.8	35
11	A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer. <i>Cancers</i> , 2022, 14, 1671.	3.7	32
12	Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization. <i>PLoS ONE</i> , 2018, 13, e0193643.	2.5	27
13	Current knowledge for pyridoxine-dependent epilepsy: a 2016 update. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 5-20.	2.4	26
14	Neuronal apoptosis inhibitory protein (NAIP) localizes to the cytokinetic machinery during cell division. <i>Scientific Reports</i> , 2017, 7, 39981.	3.3	23
15	Direct health-care costs for children diagnosed with genetic diseases are significantly higher than for children with other chronic diseases. <i>Genetics in Medicine</i> , 2019, 21, 1049-1057.	2.4	20
16	Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2021, 48, 504-511.	0.5	18
17	Genetic linkage analysis of Canadian spinal muscular atrophy kindreds using flanking microsatellite 5q13 polymorphisms. <i>Human Genetics</i> , 1993, 90, 501-4.	3.8	16
18	SMA genes: deleted and duplicated. <i>Nature Genetics</i> , 1995, 9, 112-113.	21.4	16

#	ARTICLE	IF	CITATIONS
19	DLG4-related synaptopathy: a new rare brain disorder. <i>Genetics in Medicine</i> , 2021, 23, 888-899.	2.4	16
20	Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Phenylketonuria. <i>Pediatrics</i> , 2021, 148, .	2.1	16
21	High-throughput DNA Extraction and Genotyping of 3dpf Zebrafish Larvae by Fin Clipping. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	15
22	Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 12.	2.7	15
23	Sense in Antisense Therapy for Spinal Muscular Atrophy. <i>New England Journal of Medicine</i> , 2012, 366, 761-763.	27.0	14
24	Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen. <i>Npj Genomic Medicine</i> , 2017, 2, 14.	3.8	14
25	VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 4.	2.7	13
26	cDNA cloning and the 5'genomic organization of Naip2, a candidate gene for murine Legionella resistance. <i>Mammalian Genome</i> , 1999, 10, 761-763.	2.2	11
27	The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities. <i>Paediatrics and Child Health</i> , 2018, 23, 20-26.	0.6	11
28	Transcriptomic RNAseq drug screen in cerebrocortical cultures: toward novel neurogenetic disease therapies. <i>Human Molecular Genetics</i> , 2018, 27, 3206-3217.	2.9	11
29	Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys. <i>Trials</i> , 2017, 18, 603.	1.6	9
30	Sodium Channel Inhibitors Reduce DMPK mRNA and Protein. <i>Clinical and Translational Science</i> , 2015, 8, 298-304.	3.1	8
31	Differential regulation of autophagy by STAU1 in alveolar rhabdomyosarcoma and nonâ€transformed skeletal muscle cells. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 851-870.	4.4	7
32	Ontario Newborn Screening for Spinal Muscular Atrophy: The First Year. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 821-823.	0.5	7
33	A National Spinal Muscular Atrophy Registry for Real-World Evidence. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 810-815.	0.5	6
34	Human Growth Hormone Increases SMN Expression and Survival in Severe Spinal Muscular Atrophy Mouse Model. <i>Journal of Neuromuscular Diseases</i> , 2014, 1, 65-74.	2.6	5
35	High-throughput kinome-RNAi screen identifies protein kinase R activator (PACT) as a novel genetic modifier of CUG foci integrity in myotonic dystrophy type 1 (DM1). <i>PLoS ONE</i> , 2021, 16, e0256276.	2.5	3
36	Human Growth Hormone Increases SMN Expression and Survival in Severe Spinal Muscular Atrophy Mouse Model. <i>Journal of Neuromuscular Diseases</i> , 2014, 1, 65-74.	2.6	3

#	ARTICLE	IF	CITATIONS
37	Pharmacologic normalization of pathogenic dosage underlying genetic diseases: an overview of the literature and path forward. <i>Emerging Topics in Life Sciences</i> , 2019, 3, 53-62.	2.6	1
38	Separating the Wheat from the Chaff: The Use of Upstream Regulator Analysis to Identify True Differential Expression of Single Genes within Transcriptomic Datasets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6295.	4.1	1
39	The Search for Pompe Patients in Canada: Assessing Feasibility of a National Disease Registry to Facilitate Research. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, S45-S46.	2.6	0
40	The determination of purine crystal structures: an overlooked prequel to the discovery of the double helix. <i>Genome</i> , 2019, 62, 43-44.	2.0	0
41	NAIP expression increases in a rat model of liver mass restoration. <i>Journal of Molecular Histology</i> , 2021, 52, 113-123.	2.2	0
42	The Search for Pompe Patients in Canada: Assessing Feasibility of a National Disease Registry to Facilitate Research. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, S45-S46.	2.6	0